JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

CareDx Inc

Cerrado

SectorSanidad

21.23 6.74

Resumen

Variación precio

24h

Actual

Mínimo

19.6

Máximo

21.41

Métricas clave

By Trading Economics

Ingresos

-5.8M

-4.1M

Ventas

8.3M

108M

P/B

Media del Sector

14.645

60.328

BPA

0.12

Margen de beneficios

-3.79

Empleados

761

EBITDA

-5.7M

1.5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+21.18% upside

Dividendos

By Dow Jones

Próximas Ganancias

28 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

95M

1.1B

Apertura anterior

14.49

Cierre anterior

21.23

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

99 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 00:00 UTC

Ganancias

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 abr 2026, 00:00 UTC

Ganancias

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 abr 2026, 23:47 UTC

Charlas de Mercado

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 abr 2026, 23:43 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 abr 2026, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 abr 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 abr 2026, 23:13 UTC

Adquisiciones, fusiones, absorciones

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 abr 2026, 22:33 UTC

Ganancias

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 abr 2026, 22:17 UTC

Ganancias

PLS Executed Offtake Agreement With Ronbay

23 abr 2026, 22:17 UTC

Ganancias

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 abr 2026, 22:16 UTC

Ganancias

PLS Commences Commissioning of Midstream Demonstration Plant

23 abr 2026, 22:15 UTC

Ganancias

PLS Group Reaffirms FY26 Guidance for All Metrics

23 abr 2026, 22:14 UTC

Ganancias

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 abr 2026, 22:14 UTC

Ganancias

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 abr 2026, 22:13 UTC

Ganancias

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 abr 2026, 22:12 UTC

Ganancias

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 abr 2026, 22:12 UTC

Ganancias

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 abr 2026, 22:11 UTC

Ganancias

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 abr 2026, 22:10 UTC

Ganancias

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 abr 2026, 22:09 UTC

Ganancias

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 abr 2026, 22:08 UTC

Ganancias

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 abr 2026, 22:04 UTC

Ganancias

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 abr 2026, 21:56 UTC

Charlas de Mercado
Ganancias

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 abr 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 abr 2026, 21:27 UTC

Ganancias

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 abr 2026, 21:25 UTC

Ganancias

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 abr 2026, 21:24 UTC

Ganancias

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 abr 2026, 21:24 UTC

Ganancias

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 abr 2026, 21:21 UTC

Ganancias

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 abr 2026, 21:21 UTC

Ganancias

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

21.18% repunte

Estimación a 12 Meses

Media 25 USD  21.18%

Máximo 28 USD

Mínimo 21 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

2

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

99 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat